Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections

Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders

Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics

Novartis acquires DTx Pharma to develop siRNA therapies

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025